• Year-on-year, leading companies
    trust GBI Research's clinical & competitive research
Who We Help
Financial Institutions & the Investment Community
You are here:
Who we help >
Financial Institutions & the Investment Community

Financial Institutions & the Investment Community

GBI Research supports individuals and teams looking for companies and products that offer a competitive advantage, which present attractive investment opportunities.

Our data and analyses support critical business processes in a number of ways, including:

  • Pinpointing breakthrough innovation and the market potential that represents

  • Identifying the most pioneering and innovative drug discovery and small biotech companies

  • Differentiating between clinically interesting programs and those with commercial breakthrough potential

  • Benchmarking investment candidates based upon crucial factors, including unmet need, risk-profile, development program, regulatory and reimbursement issues

  • Rigorous assessment of the current and future licensing and co-development deals landscape

  • Robust multi-scenario market forecasts as a vital input into divestment strategy formulation

Analyst Views

28 Nov 16
Repurposing Type 2 Diabetes Mellitus Drugs for Alzheimer’s ....
In this Analyst View, Fiona Chisholm, Analyst for GBI Research, discusses the potential f.....
Read post
21 Nov 16
Urological Cancer Treatment Landscape to be Transformed by ....
In this Analyst View, Adam Bradbury, Associate Analyst for GBI Research, discuses current.....
Read post

White Papers

22 Nov 16
An Exploration of Novel and Repositioned Calcium Transport ....
This whitepaper discusses the increasing interest in using repositioned calcium transport....
Read post
14 Nov 16
The Emerging Field of Cannabinoid-Based Products....
This white paper discusses the current commercial landscape for cannabinoid-based product....
Read post

Press Releases

20 Mar 17
Asia-Pacific non-small cell lung cancer market to soar to $....
The non-small cell lung cancer (NSCLC) market in the Asia-Pacific (APAC) region will more.....
Read post
16 Mar 17
As fatty liver disease prevalence soars, pharma companies l....
Due to the increasing global prevalence of fatty liver disease (FLD), which comprises a s.....
Read post